Bispecific antibodies improve progression-free survival and overall survival in patients with solid tumors
Bispecific antibodies improve survival for patients with solid tumors
This meta-analysis of 3505 patients with solid tumors found that bispecific antibodies significantly improved progression-free survival (HR …
A new type of antibody treatment shows promise in extending life and slowing cancer growth for patients with solid tumors.
Bispecific antibodies improve progression-free survival and overall survival in patients with solid tumors
Bispecific Antibodies Show Improved Survival for Solid Tumors
This meta-analysis of 3,505 patients with solid tumors found that bispecific antibodies significantly improved progression-free survival (HR…
New analysis suggests bispecific antibodies may improve survival and slow tumor growth for patients with solid tumors compared to other trea…
Clinically significant CMV infection occurs in 9% of patients receiving bispecific antibodies for hematologic malignancies
Bispecific Antibodies Linked to Lower Rates of CMV Infection
This meta-analysis of 23 studies and a single-center cohort evaluated bispecific antibody use in multiple myeloma, B-cell lymphoma, and acut…
New data shows that patients receiving bispecific antibodies for certain blood cancers may have lower rates of serious CMV infections.
Next-generation engineered constructs aim to overcome immunosuppressive tumor microenvironments in refractory malignancies
New framework aims to improve treatment for solid tumors
This systematic review synthesizes clinical data regarding CAR-T cells and bispecific antibodies for solid tumors and refractory malignancie…
Doctors are looking at new ways to use CAR-T cells and bispecific antibodies earlier in the treatment of hard-to-treat cancers.
Review of BsAb-armed T cells for solid tumors and CAR-T and BsAb therapy
BsAb-armed T cells may help solid tumors fight back against cancer
This narrative review synthesizes evidence on BsAb-armed T cells (EATs) for solid tumors, comparing them to CAR-T and BsAb therapy. The auth…
New review suggests BsAb-armed T cells could improve tumor infiltration and reduce immune escape in solid tumors compared to standard CAR-T …
Narrative review discusses antibody targeting of the TNF–TNFR2 axis in cancer with noted limitations
Antibodies targeting TNFR2 show promise for cancer treatment
This narrative review examines antibody targeting of the TNF–TNFR2 axis, including monoclonal antibodies, antibody–drug conjugates, and bisp…
A narrative review suggests antibodies targeting the TNF–TNFR2 axis may offer new cancer treatment options, though more research is needed.
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.